Novartis Ag (NVSEF) Free Cash Flow (2009 - 2026)

Novartis Ag has disclosed Free Cash Flow across 16 years of filings, most recently posting $346.0 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $346.0 million, up 36.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.3 billion (down 38.07% YoY), and the FY2025 annual result was $17.6 billion, up 8.26% from the prior year.
• Free Cash Flow came in at $346.0 million for Q1 2026 at Novartis Ag, down from $609.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $7.7 billion in Q4 2024 to a low of $168.0 million in Q1 2023.
• The 5-year median for Free Cash Flow is $354.0 million (2025), against an average of $2.5 billion.
• Peak annual rise in Free Cash Flow reached 36.22% in 2025, while the deepest fall reached 92.09% in 2025.
• Novartis Ag's Free Cash Flow stood at $5.7 billion in 2022, then climbed by 21.52% to $6.9 billion in 2023, then rose by 10.94% to $7.7 billion in 2024, then sank by 92.09% to $609.0 million in 2025, then sank by 43.19% to $346.0 million in 2026.
• The last three Free Cash Flow figures came in at $346.0 million (Q1 2026), $609.0 million (Q4 2025), and $354.0 million (Q3 2025), per Business Quant data.